BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23177609)

  • 21. [The treatment of acute ischemic stroke].
    Csiba L
    Orv Hetil; 2004 Nov; 145(45):2297-301. PubMed ID: 15573895
    [No Abstract]   [Full Text] [Related]  

  • 22. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
    Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
    Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasminogen activation and thrombolysis for ischemic stroke.
    Medcalf RL; Davis SM
    Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy.
    Toni D; Lorenzano S; Agnelli G; Guidetti D; Orlandi G; Semplicini A; Toso V; Caso V; Malferrari G; Fanucchi S; Bartolomei L; Prencipe M
    Cerebrovasc Dis; 2008; 25(1-2):129-35. PubMed ID: 18073466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravenous thrombolytic therapy of patients with acute cerebral infarction].
    Thomassen L; Sandset PM; Joakimsen O; Indredavik B; Russell D
    Tidsskr Nor Laegeforen; 2003 Mar; 123(5):638-9. PubMed ID: 12683192
    [No Abstract]   [Full Text] [Related]  

  • 26. Current acute stroke trials and their potential impact on the therapeutic time window.
    Schellinger PD; Köhrmann M
    Expert Rev Neurother; 2012 Feb; 12(2):169-77. PubMed ID: 22288672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
    Fonarow GC; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Grau-Sepulveda MV; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    Circulation; 2011 Feb; 123(7):750-8. PubMed ID: 21311083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis 3 to 4.5 hours after acute ischemic stroke.
    Fitzpatrick AE; Noone I; O'Shea DD
    N Engl J Med; 2008 Dec; 359(26):2840; author reply 2841. PubMed ID: 19115491
    [No Abstract]   [Full Text] [Related]  

  • 30. Thrombolytic therapy for acute ischemic stroke: risks vs benefits.
    Lindbloom EJ
    J Fam Pract; 2003 Oct; 52(10):757, 761. PubMed ID: 14529595
    [No Abstract]   [Full Text] [Related]  

  • 31. Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.
    Samaniego EA; Linfante I; Dabus G
    Tech Vasc Interv Radiol; 2012 Mar; 15(1):41-6. PubMed ID: 22464301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
    Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH
    J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.
    Lin CB; Peterson ED; Smith EE; Saver JL; Liang L; Xian Y; Olson DM; Shah BR; Hernandez AF; Schwamm LH; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):514-22. PubMed ID: 22787065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use and misuse of thrombolytic therapy within the Veterans Health Administration.
    Keyhani S; Arling G; Williams LS; Ross JS; Ordin DL; Myers J; Tyndall G; Vogel B; Bravata DM
    Med Care; 2012 Jan; 50(1):66-73. PubMed ID: 22182924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of acute ischemic stroke.
    Lewandowski C; Barsan W
    Ann Emerg Med; 2001 Feb; 37(2):202-16. PubMed ID: 11174240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thrombolytic therapy in stroke approved with reservation. Underlying evidence, practical guidelines and safety follow up].
    Wahlgren NG
    Lakartidningen; 2004 Feb; 101(8):674-7. PubMed ID: 15024940
    [No Abstract]   [Full Text] [Related]  

  • 40. Endovascular treatment strategies for acute ischemic stroke.
    Ellis JA; Youngerman BE; Higashida RT; Altschul D; Meyers PM
    Int J Stroke; 2011 Dec; 6(6):511-22. PubMed ID: 22111796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.